| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 8.9 | 11.8 | 11.1 |
| Other income | 1.6 | 1.5 | 1.5 |
| Total income | 10.5 | 13.3 | 12.6 |
| Profit before exceptional items & tax | -1.0 | 2.9 | 3.2 |
| Exceptional items | 0.1 | -0.3 | -0.0 |
| Profit before tax | -0.9 | 2.6 | 3.2 |
| Net profit | -3.2 | 1.9 | 1.2 |
| Operating margin | -8.6% | 19.5% | 25.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | -19.80% |
|---|
BSE results filing, NSE: ZENOTECH. Figures extracted from the filing.
Zenotech Laboratories Ltd: key numbers
- Share price
- ₹41.85
- Market cap
- ₹255.4 Cr
- Revenue (annual)
- ₹43.61 Cr
- Net profit (annual)
- ₹-1.07 Cr
- P/E (TTM)
- -101.5×Sector 47.4×
- Promoter holding
- 68.84%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zenotech Laboratories Ltd
All →Zenotech Laboratories Annual General Meeting
Zenotech Laboratories Limited concluded its 37th Annual General Meeting. Shareholders approved the adoption of financial statements and re-appointment of Mr. Jignesh Anantray Goradia as Director.
Zenotech Laboratories Annual General Meeting
Zenotech Laboratories Limited will hold its 37th Annual General Meeting on September 25, 2026, via video conferencing. The cut-off date for voting is September 18, 2026.
Zenotech Laboratories Q1 FY27 Results: Net Loss of ₹0.5 Cr
Zenotech Laboratories Ltd reported revenue from operations of ₹9.6 Cr (+11.6% YoY) and a net loss of ₹0.5 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.5 Cr
Zenotech Laboratories Board Meeting Date
Zenotech Laboratories will hold a board meeting on July 28, 2026. The board will consider unaudited standalone financial results for the June 2026 quarter.
Zenotech Laboratories Other Announcement
Zenotech Laboratories submitted its Annual Secretarial Compliance Report for financial year 2025-26. The report highlights governance adherence and specific non-compliance regarding subsidiary financial disclosures.
Zenotech Laboratories Financial Results
Zenotech Laboratories Ltd approved audited standalone financial results for the quarter and year ended March 31, 2026. The Board met on April 29, 2026, to review performance and the auditor's report. These results were prepared in accordance with Ind AS and Regulation 33 of SEBI Listing Regulations.